

**DEPARTMENT OF NEUROPSYCHIATRY
2003 - PRESENT**

CURRENTLY ONGOING RESEARCH STUDIES:

The Study of Olanzapine plus Fluoxetine in Combination for Treatment-Resistant Depression without Psychotic Features, David F. Briones, M.D., Eli Lilly and Company.

Alzheimer's Disease in El Paso's Residential Elderly Population, Martin Guerrero, M.D., Center for Border Health

A Mastery-Based Weight Prevention Program for the Management of Antipsychotic-Related Weight Gain Among Mexican-American patients: A Pilot Project, David F. Briones, M.D., Eli Lilly and Company.

An Olanzapine Model for Relieving Anxiety in Schizophrenic Patients and Implications for Enhanced Compliance, James A. Wilcox, D.O., Ph.D., Eli Lilly and Company.

A Neurogenetic Investigation of Patients with Schizophrenia Spectrum Disorders and Participating Family Members, James A. Wilcox, D.O., Ph.D., National Institute of Mental Health.

Surveillance for Multiple Sclerosis and Amyotrophic Lateral Sclerosis in Texas, Richard Brower, M.D., Texas Department of Health.